CLL
Conference Coverage
ECG finding predicts AFib in ibrutinib-treated CLL
NEW YORK – Left atrial abnormality as measured by electrocardiogram in ibrutinib-treated patients with chronic lymphocytic leukemia can identify...
Conference Coverage
In good-candidate CLL, don’t wait too long for alloHCT
NEW YORK – Allogeneic hematopoietic stem cell transplantation (alloHCT) using HLA-compatible donors results in excellent long-term progression-...
Conference Coverage
Ibrutinib response in CLL/SLL less affected by select risk factors
NEW YORK – Risk factors associated with poor outcomes in chronic lymphocytic leukemia/small lymphocytic leukemia patients treated with standard...
Conference Coverage
Targeted drugs transform CLL management
NEW YORK – Patients with CLL are living longer, creating new challenges in long-term care.
Conference Coverage
Venetoclax produces durable effects in relapsed/refractory CLL
ORLANDO – Venetoclax may provide durable responses – even with treatment discontinuation – in patients with relapsed or refractory chronic...
Conference Coverage
Advanced CLL treatment approach depends on comorbidity burden
The choice of first-line therapy in symptomatic chronic lymphocytic leukemia patients depends largely on comorbidity burden.
From the Journals
CLL boost in PFS came at high cost in side effects
Add-on idelalisib boosted the progression-free survival of patients with relapsed and refractory chronic lymphocytic leukemia, but at a price.
Conference Coverage
CAR designers report high B-cell cancer response rates
A CAR-T cell construct consisting of autologous CD4-positive and CD-8 positive T cells delivered in a single infusion was associated with high...
From the Journals
Ublituximab was safe, highly active in rituximab-pretreated B-cell NHL, CLL
Ublituximab had good safety and antitumor activity in rituximab-relapsed or -refractory B-cell non-Hodgkin lymphoma or chronic lymphocytic...
From the Journals
In CLL, specific mutation is key to ibrutinib resistance
Specific mutations precede relapse in ibrutinib-treated CLL, offering an opportunity to target asymptomatic clonal expression with novel therapies...
Conference Coverage
In active CLL with deletion 17p, consider trial enrollment
NEW YORK – Outside of clinical trials, therapy for early stage chronic lymphocytic leukemia in patients with deletion of the short arm of...